Back to top
more

TG Therapeutics (TGTX)

(Real Time Quote from BATS)

$20.32 USD

20.32
5,277,584

+0.33 (1.65%)

Updated Aug 8, 2024 09:34 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Tirthankar Chakraborty headshot

5 Stocks to Watch Out For Remarkable Earnings Acceleration

Western Digital (WDC), DocuSign (DOCU) & Kaiser Aluminum (KALU) are some of the stocks that at present are showing superb earnings acceleration, which may lead to an uptick in the stock price.

TG Therapeutics (TGTX) Reports Q1 Loss, Lags Revenue Estimates

TG Therapeutics (TGTX) delivered earnings and revenue surprises of -32.69% and -20.14%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Medical Product Stock Q1 Earnings on May 10: MRVI, TGTX & More

The sector's Q1 results are likely to reflect solid earnings and revenue growth on strong base business recovery.

Earnings Preview: TG Therapeutics (TGTX) Q1 Earnings Expected to Decline

TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Strength Seen in TG Therapeutics (TGTX): Can Its 6.7% Jump Turn into More Strength?

TG Therapeutics (TGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Company News for Mar 3, 2021

Companies in The News Are: KSS,AZO,TGTX,KTB

TG Therapeutics (TGTX) Reports Q4 Loss, Lags Revenue Estimates

TG Therapeutics (TGTX) delivered earnings and revenue surprises of -24.56% and -5.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Trina Mukherjee headshot

3 Soaring MedTech Stocks That Might Lose Ground in 2021

Despite MedTech industry's bright prospects in 2021, investors should be wary of stocks like BLFS, STAA and TGTX, given their unfavorable Zacks Rank and weak fundamentals.

Are Options Traders Betting on a Big Move in TG Therapeutics (TGTX) Stock?

Investors need to pay close attention to TG Therapeutics (TGTX) stock based on the movements in the options market lately.

Company News for Dec 11, 2020

Companies in The News Are: CIEN,ASO,DIS,TGTX

TG Therapeutics (TGTX) Reports Q3 Loss, Lags Revenue Estimates

TG Therapeutics (TGTX) delivered earnings and revenue surprises of -78.05% and -5.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

TG Therapeutics (TGTX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TG Therapeutics (TGTX) Reports Q2 Loss, Lags Revenue Estimates

TG Therapeutics (TGTX) delivered earnings and revenue surprises of -46.88% and -5.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Are You Looking for a Top Momentum Pick? Why TG Therapeutics (TGTX) is a Great Choice

Does TG Therapeutics (TGTX) have what it takes to be a top stock pick for momentum investors? Let's find out.

TG Therapeutics (TGTX) Moves to Buy: Rationale Behind the Upgrade

TG Therapeutics (TGTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Will TG Therapeutics (TGTX) Report Negative Q1 Earnings? What You Should Know

TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TG Therapeutics (TGTX) Upgraded to Buy: What Does It Mean for the Stock?

TG Therapeutics (TGTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Options Traders Expect Huge Moves in TG Therapeutics (TGTX) Stock

Investors need to pay close attention to TG Therapeutics (TGTX) stock based on the movements in the options market lately.

TG Therapeutics (TGTX) Catches Eye: Stock Jumps 8.9%

TG Therapeutics (TGTX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

TG Therapeutics' Shares Soar on Positive Early-Stage Data

TG Therapeutics (TGTX) announces positive first clinical data from its once daily, oral, BTK inhibitor, TG-1701, as a single agent and as a triple therapy in combination.

Can Core MedSurg Segment Drive Stryker's (SYK) Q1 Earnings?

Solid segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine along with an upbeat 2019 view are likely to support Stryker (SYK) in Q1. But integration risks might be a dampener.

Company News For Apr 2, 2019

Companies in the news are: JNJ, SCOR, VFF and TGTX

Is the Options Market Predicting a Spike in TG Therapeutics (TGTX) Stock?

Investors need to pay close attention to TG Therapeutics (TGTX) stock based on the movements in the options market lately.

What Makes TG Therapeutics (TGTX) a New Strong Buy Stock

TG Therapeutics (TGTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.